Craif's Urine Cancer Test "MySignal Scan" Introduced at Shinagawa Season Terrace Health Checkup Clinic
Craif Inc. announced that its urine cancer test "MySignal Scan" has been adopted as an optional health checkup at Shinagawa Season Terrace Health Checkup Clinic. This test utilizes AI to analyze microRNAs in urine, offering early detection of cancer risk from Stage 1 for 10 types of cancer.
📋 Article Processing Timeline
- 📰 Published: April 8, 2026 at 19:00
- 🔍 Collected: April 8, 2026 at 10:31
- 🤖 AI Analyzed: April 21, 2026 at 03:11 (304h 39m after Collected)
Bio-AI startup Craif Inc. (Headquarters: Shinjuku-ku, Tokyo; Representative Director and CEO: Ryuichi Onose; hereinafter "Craif") announced that its urine cancer test "MySignal Scan" has been newly introduced as an optional health checkup at Shinagawa Season Terrace Health Checkup Clinic. This introduction creates an environment where individuals undergoing corporate health checkups and other examinations can receive a cancer risk test based on cutting-edge urinary microRNA analysis technology, raising expectations for cancer prevention and early detection.
## About "MySignal Scan"
"MySignal Scan" is a test that assesses the risk of 10 types of cancer*, including pancreatic cancer, specifically by type and from Stage 1, by extracting microRNAs from urine and analyzing them with AI. It is possible to undergo the test simply by collecting urine, without any physical burden.
Please refer to the website for details.
https://misignal.jp/
"MySignal Scan" is not a medical device. It determines risk by statistically calculating analyzed information and is not a substitute for a medical diagnosis of whether one has cancer. Even if determined to be low risk, it does not guarantee the absence of cancer or that one will not develop cancer in the future.
* Ovarian cancer and breast cancer are対象 for women only; prostate cancer is 対象 for men only.
## About Craif
Craif (pronounced "Cray-iff") is a bio-AI startup founded in 2018 dedicated to the early detection of cancer. They integrate their proprietary "NANO IP®︎ (NANO Intelligence Platform)" analysis technology, which precisely detects various biomarkers like DNA and microRNA from bodily fluids such as urine, with AI technology. They develop innovative tests that enable ultra-early detection, early treatment, and early recovery from cancer. By widely delivering the power of biotechnology and AI to society, Craif promotes its vision of "realizing a society where people can live out their full natural lifespan."
### [Company Overview]
Company Name: Craif Inc.
Representative: Ryuichi Onose, Representative Director
Established: May 2018
Capital: 100 million JPY (as of March 1, 2024)
## About "MySignal Scan"
"MySignal Scan" is a test that assesses the risk of 10 types of cancer*, including pancreatic cancer, specifically by type and from Stage 1, by extracting microRNAs from urine and analyzing them with AI. It is possible to undergo the test simply by collecting urine, without any physical burden.
Please refer to the website for details.
https://misignal.jp/
"MySignal Scan" is not a medical device. It determines risk by statistically calculating analyzed information and is not a substitute for a medical diagnosis of whether one has cancer. Even if determined to be low risk, it does not guarantee the absence of cancer or that one will not develop cancer in the future.
* Ovarian cancer and breast cancer are対象 for women only; prostate cancer is 対象 for men only.
## About Craif
Craif (pronounced "Cray-iff") is a bio-AI startup founded in 2018 dedicated to the early detection of cancer. They integrate their proprietary "NANO IP®︎ (NANO Intelligence Platform)" analysis technology, which precisely detects various biomarkers like DNA and microRNA from bodily fluids such as urine, with AI technology. They develop innovative tests that enable ultra-early detection, early treatment, and early recovery from cancer. By widely delivering the power of biotechnology and AI to society, Craif promotes its vision of "realizing a society where people can live out their full natural lifespan."
### [Company Overview]
Company Name: Craif Inc.
Representative: Ryuichi Onose, Representative Director
Established: May 2018
Capital: 100 million JPY (as of March 1, 2024)